Christina Dillmann

Title: Christina Dillmann: Innovator in Immunology

Introduction

Christina Dillmann is a prominent inventor based in Frankfurt, Germany. She has made significant contributions to the field of immunology, particularly through her innovative research on interleukin-38. Her work has implications for the treatment and prevention of autoimmune disorders.

Latest Patents

Christina Dillmann holds a patent for an N-terminally truncated interleukin-38 protein. This invention pertains to the truncated IL-38 protein, functional variants, nucleic acids, and vectors encoding the truncated peptide. The research demonstrates that IL-38 is N-terminally processed and that the truncated version acts as an antagonist of immune activation in macrophages. This discovery indicates potential therapeutic uses for the truncated cytokine in autoimmune disorders. The patent also includes pharmaceutical compositions comprising the truncated IL-38 protein and methods for screening modulators of its function.

Career Highlights

Christina Dillmann is affiliated with the Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., a leading research organization in Germany. Her work has been instrumental in advancing the understanding of immune responses and developing new therapeutic strategies.

Collaborations

Some of her notable coworkers include Michael John Parnham and Gerd Geisslinger, who have collaborated with her on various research projects.

Conclusion

Christina Dillmann's innovative research and patent contributions are paving the way for new treatments in immunology. Her work exemplifies the impact of scientific innovation on healthcare and the potential for improving patient outcomes.